The proportion of patients achieving mT2* ≥10 ms and ≥10% relative increase from baseline when treated with DFX-DFO combination followed by DFX monotherapy over 24 months. † indicates the last observation carried forward. FAS, full analysis set (patients who remained on treatment with an available assessment within each visit window); ITT, intent-to-treat (including all patients enrolled).